Nabriva Therapeutics is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company engaged in the research, development and commercialization of anti-infective agents to treat serious infections. Co. has approval from the U.S. Food and Drug Administration for XENLETA for the treatment of adults with community-acquired bacterial pneumonia. XENLETA is an oral and intravenous treatment in the pleuromutilin class of antibiotics available for the systematic administration in humans. Co.'s CONTEPO is a potentially epoxide antibiotic for intravenous use in the U.S. for complicated urinary tract infections. Co. may develop XENLETA and CONTEPO for additional indications.